Clinical trials for Beta-O2 product aims to cure type 1 diabetes

Mon, 17 Nov 2014
The ΒAir bio-artificial pancreas, developed in Israel, is going into clinical trials to determine if it can find a cure for type 1 diabetes.

Israel's Beta-O2 developed the implantable bio-artificial pancreas, which was recently implanted in the first of eight diabetes patients in Sweden.

Islet cell encapsulation

Islet cell encapsulation is being investigated as a cure for type 1 diabetes, however, immunosuppressant drugs must then be taken for the rest of their lives.

To prevent this, Beta-O2's encapsulation technique protects the transplanted cells from destruction in the immune system, which characterises type 1 diabetes.

Beta-O2's encapsulation has unique features that provide oxygen into these islet cells, which are "huge consumers of oxygen," said Dan Gelvan, Chairman of Beta-O2.

"This company has taken an engineering approach to finding a way to make sure there is an active supply of oxygen to the transplanted cells," Gelvan added.

Two-year pilot study

This two-year pilot study is set to cost $1 million, enrolling eight participants and evaluating the safety, survival and function of the implanted Beta-O2 system.

"Ours is a biological device that is meant to restore the original effect of having islet cells," Gelvan added.

"You have all elements of a functioning pancreas in response to the body's varying glucose levels. We are actually simulating and emulating the functionality of an organ".

When speaking about the device's lifespan, Gelvan said: "We don't know yet how long it lasts, but conventional islet transplants continue to function well for eight to nine years. We hope that because we've created a protected microenvironment fed by oxygen, it will last even longer".
Leave a Comment
Login via Facebook, Yahoo! and Hotmail
Have your full say in the Diabetes Forum
Your comments may be moderated. Please report any spam, illegal, offensive or libellous posts.